u.s.

Instil Bio Announces U.S. F.D.A. Clearance of Investigational New Drug (IND) Application for AXN-2510, a PD-L1xVEGF Bispecific Antibody, for a Phase 1 Trial in Relapsed/Refractory Solid Tumors

July 02, 2025 06:00 ET  | Source: Instil Bio US phase 1 trial of ‘2510 is expected to be initiated before…

5 months ago

IMG Launches First ‘Student Journey Scholarship’ for International Students in the U.S.

INDIANAPOLIS, July 1, 2025 /PRNewswire/ -- IMG (International Medical Group), an award-winning global insurance benefits and assistance services company, is…

5 months ago

XTEND Reality Inc. Debuts New U.S. Headquarters and Drone Production Facility in Tampa, Driving Innovation and National Security

New facility strengthens America's domestic drone production capacity while bringing high-tech jobs and investment to Florida TAMPA, Fla., July 1,…

5 months ago
Show previous Posts